1 / 3

Enhanced Local and Regional Recurrence-Free Survival in CALOR Trial: Impact of Prior Chemotherapy

Explore the CALOR trial's updated findings on disease-free survival with a median follow-up of 5 years. Evaluate the influence of prior chemotherapy, radiotherapy, hormone therapy, and anti-HER2 treatment in recurrent breast cancer. Benefit from insights on hormone receptor status and recurrence site stratification for informed treatment decisions.

sidone
Download Presentation

Enhanced Local and Regional Recurrence-Free Survival in CALOR Trial: Impact of Prior Chemotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Essai CALOR (1) Rechute locale et/ou régionale Stratification • Récepteur aux hormones • Site de récidive • Chimiothérapie antérieure R Pas de chimiothérapie Chimiothérapie Radiothérapie, hormonothérapie, anti-HER2 si approprié D’après Aebi S et al., abstr. S3-2 actualisé

  2. Survie sans maladie (suivi médian de 5 ans) Essai CALOR (2) % 100 (n = 162) 80 69 % 60 Chimiothérapie 57 % Pas de chimiothérapie 40 20 0 0 1 2 3 4 5 6 D’après Aebi S et al., abstr. S3-2 actualisé

  3. Essai CALOR (3) Survie globale (suivi médian de 5 ans) % (n = 162) 100 88 % 80 76 % 60 Chimiothérapie Pas de chimiothérapie 40 20 0 0 1 2 3 4 5 6 Années D’après Aebi S et al., abstr. S3-2 actualisé

More Related